Dr. Toshio Tanaka
My Social Links

Dr. Toshio Tanaka

Professor
Osaka University Graduate School of Medicine, Japan

Highest Degree
Ph.D. in Internal Medicine from Osaka University, Japan

Share this Profile

Area of Interest:

Medicine
100%
Ageing Mechanisms
62%
Immunology
90%
Inflammation
75%
Internal Medicine
55%

Research Publications in Numbers

Books
0
Chapters
0
Articles
0
Abstracts
0

Selected Publications

  1. Tanaka, T., M. Narazaki and T. Kishimoto, 2014. Interleukin-6. In: Encyclopedia of Medical Immunology, Mackay, I.R. and N.R. Rose (Eds.). Chapter 36, Springer, New York.
  2. Tanaka, T., M. Narazaki, K. Masuda and T. Kishimoto, 2013. Interleukin-6: Pathogenesis and treatment of autoimmune inflammatory diseases. Inflammat. Regenerat., 33: 54-65.
    Direct Link  |  
  3. Tanaka, T., A. Ogata, Y. Shima, M. Narazaki, A. Kumanogoh and T. Kishimoto, 2013. IL-6 Targeting Strategy for Various Immune-Mediated Diseases other than Rheumatoid Arthritis: An Update Review. In: Interleukin-6: Genetics, Clinical Applications and Role in Disease, D'Aquino, J. and E.N. DeVito (Eds.). Chapter 2, Nova Science Publishers, USA., pp: 61-110.
  4. Tanaka, T., A. Ogata and T. Kishimoto, 2013. Targeting of interleukin-6 for the treatment of rheumatoid arthritis: A review and update. Rheumatol. Curr. Res., Vol. S4. 10.4172/2161-1149.S4-002.
    CrossRef  |  
  5. Tanaka, T., A. Ogata and M. Narazaki, 2013. Tocilizumab: An updated review of its use in the treatment of rheumatoid arthritis and its application for other immune-mediated diseases. Clin. Med. Insights Therapeutics, 5: 33-52.
    CrossRef  |  
  6. Tanaka, T., 2013. Flavonoids for allergic diseases: Present evidence and future perspective. Curr. Pharm. Des., (In Press). .
    PubMed  |  Direct Link  |  
  7. Tanaka, T., 2013. Flavonoids as complementary medicine for allergic diseases: current evidence and future prospects. OA Alternative Med., Vol. 1. .
    Direct Link  |  
  8. Tanaka, T., 2013. Can IL-6 blockade rectify imbalance between Tregs and Th17 cells? Immunotherapy, 5: 695-697.
    CrossRef  |  PubMed  |  
  9. Tanaka, T. and R. Takahashi, 2013. Flavonoids and asthma. Nutrients, 5: 2128-2143.
    CrossRef  |  
  10. Shima, Y., N. Hosen, T. Hirano, J. Arimitsu and S. Nishida, 2013. Expansion of range of joint motion following treatment of systemic sclerosis with tocilizumab. Modren Rheumatol., (In Press). 10.1007/s10165-013-0855-6.
    CrossRef  |  
  11. Ogawa, M., T. Matsuda, A. Ogata, T. Hamasaki, A. Kumanogoh, T. Toyofuku and T. Tanaka, 2013. DNA damage in rheumatoid arthritis: An age-dependent increase in the lipid peroxidation-derived DNA adduct, heptanone-etheno-2-deoxycytidine. Autoimmune Dis., (In Press). 10.1155/2013/183487.
    CrossRef  |  
  12. Ogata, A., T. Tanaka and A. Kumanogoh, 2013. Efficacy of Anti-IL-6 Therapy for Seronegative Spondyloarthropathy. In: Ankylosing Spondylitis: Symptoms, Treatment and Potential Complications, Boysen, C.B. (Ed.). Chap. 2, Nova Science Publishers Inc., New York, pp: 37-52.
  13. Ogata, A., K. Tanimura, T. Sugimoto, T. Inoue and Y. Urata et al., 2013. A phase 3 study of the efficacy and safety of subcutaneous versus intravenous tocilizumab monotherapy in patients with rheumatoid arthritis (MUSASHI). Arthritis Care Res., (In Press). 10.1002/acr.22110.
    CrossRef  |  
  14. Ogata, A., A. Morishima, Y. Yoshida, T. Tanaka and A. Kumanogoh, 2013. IL-6 Targeting Strategy for Rheumatoid Arthritis. In: Interleukin-6: Genetics, Clinical Applications and Role in Disease, D'Aquino, J. and E.N. DeVito (Eds.). Chapter 3, Nova Science Publishers, USA., pp: 111-149.
  15. Nakaoka, Y., K. Higuchi, Y. Arita, M. Otsuki and K. Yamamoto et al., 2013. Tocilizumab for the treatment of the patients with refractory Takayasu arteritis. Int. Heart J., 54: 405-411.
    PubMed  |  Direct Link  |  
  16. Hishitani, Y., A. Ogata, Y. Shima, T. Hirano and K. Ebina et al., 2013. Retention of tocilizumab and anti-tumour necrosis factor drugs in the treatment of rheumatoid arthritis. Scand. J. Rheumatol., 42: 253-259.
    CrossRef  |  PubMed  |  Direct Link  |  
  17. Yokota, S., T. Tanaka and T. Kishimoto, 2012. Efficacy, safety and tolerability of tocilizumab in patients with systemic juvenile idiopathic arthritis. Ther. Adv. Musculoskelet. Dis., 4: 387-397.
    CrossRef  |  Direct Link  |  
  18. Tanaka, T., M. Narazaki and T. Kishimoto, 2012. Therapeutic targeting of the interleukin-6 receptor. Ann. Rev. Pharmacol. Toxicol., 52: 199-219.
    CrossRef  |  Direct Link  |  
  19. Tanaka, T., A. Ogata, Y. Shima, M. Narazaki, A. Kumanogoh and T. Kishimoto, 2012. Therapeutic implications of tocilizumab, a humanized anti-interleukin-6 receptor antibody, for various immune-mediated diseases: An update review. Curr. Rheumatol. Rev., 8: 209-226.
    Direct Link  |  
  20. Tanaka, T., 2012. Efficacy of Flavonoids for Patients with Japanese Cedar Pollinosis. In: Current Insights in Pollen Allergens, Jimenez-Lopez, J.C. (Ed.). Chapter 6, INTECH Open Access Publisher, Croatia, pp: 103-122.
  21. Tanaka, T. and T. Kishimoto, 2012. Targeting interleukin-6: All the way to treat autoimmune and inflammatory diseases. Int. J. Biol. Sci., 8: 1227-1236.
    CrossRef  |  PubMed  |  Direct Link  |  
  22. Tanaka, T. and T. Kishimoto, 2012. Immunotherapy of tocilizumab for rheumatoid arthritis. J. Clin. Cell Immunol., S6: 1-8.
    CrossRef  |  Direct Link  |  
  23. Tanaka, T. and T. Kishimoto, 2012. Immunotherapeutic implication of IL-6 blockade. Immunotherapy, 4: 87-105.
    CrossRef  |  Direct Link  |  
  24. Tada, A., N. Hashida, T. Tanaka and K. Nishida, 2012. Anti-interleukin-6 receptor antibody therapy-induced retinopathy in a patient with rheumatoid arthritis. Case Report Rheumatol., Vol. 2012. 10.1155/2012/270315.
    CrossRef  |  Direct Link  |  
  25. Ogata, A., T. Hirano, Y. Hishitani and T. Tanaka, 2012. Safety and efficacy of tocilizumab for the treatment of rheumatoid arthritis. Clin. Med. Insights Arthritis Musculoskelet. Disord., 5: 27-42.
    CrossRef  |  PubMed  |  Direct Link  |  
  26. Ogata, A., N. Umegaki, I. Katayama, A. Kumanogoh and T. Tanaka, 2012. Psoriatic arthritis in two patients with an inadequate response to treatment with tocilizumab. Joint Bone Spine, 79: 85-87.
    CrossRef  |  Direct Link  |  
  27. Ogata, A., A. Kumanogoh and T. Tanaka, 2012. Pathological role of interleukin-6 in psoriatic arthritis. Arthritis, Vol. 2012. 10.1155/2012/713618.
    CrossRef  |  Direct Link  |  
  28. Ogata, A. and T. Tanaka, 2012. Tocilizumab for the treatment of rheumatoid arthritis and other systemic autoimmune diseases: Current perspectives and future directions. Int. J. Rheumatol., 10.1155/2012/946048.
    CrossRef  |  Direct Link  |  
  29. Kitaba, S., H. Murota, M. Terao, H. Azukizawa and F. Shima et al., 2012. Blockade of interleukin-6 receptor alleviates disease in mouse model of scleroderma. Am. J. Pathol., 180: 165-176.
    CrossRef  |  Direct Link  |  
  30. Hirano, T., N. Ohguro, S. Hohki, K. Hagihara and Y. Shima et al., 2012. A case of Behcet's disease treated with a humanized Anti-interleukin-6 receptor antibody, tocilizumab. Modern Rheumatol., 22: 298-302.
    CrossRef  |  Direct Link  |  
  31. Harigai, M., Y. Tanaka, S. Maisawa and The JA21963 Study Group, 2012. Safety and efficacy of various dosages of ocrelizumab in Japanese patients with rheumatoid arthritis with an inadequate response to methotrexate therapy: A placebo-controlled double-blind parallel-group study. J. Rheumatol., 39: 486-495.
    CrossRef  |  PubMed  |  Direct Link  |  
  32. Arnaud, L., H. Devilliers, S.L. Peng, A. Mathian and N. Costedoat-Chalumeau et al., 2012. The relapsing polychondritis disease activity index: Development of a disease activity score for relapsing polychondritis. Autoimmun. Rev., 12: 204-209.
    CrossRef  |  Direct Link  |  
  33. Tanaka, T., T. Hirano, M. Kawai, J. Arimitsu and K. Hagihara et al., 2011Tanaka, T., T. Hirano, M. Kawai, J. Arimitsu and K. Hagihara et al., 2011. Flavonoids, Natural Inhibitors of Basophil Activation. In: Cell Biology Research Progress, Vellis, P.K. (Ed.). Nova Science Publishers, New York, pp: 61-72.
  34. Tanaka, T., M. Narazaki and T. Kishimoto, 2011. Anti-interleukin-6 receptor antibody, tocilizumab, for the treatment of autoimmune diseases. FEBS Lett., 585: 3699-3709.
    CrossRef  |  Direct Link  |  
  35. Tanaka, T., K. Hagihara, Y. Shima, M. Narazaki, A. Ogata and A. Kumanogoh, 2011. Tocilizumab, a humanized Anti-interleukin-6 receptor antibody, for the treatment of autoimmune disorders. Drug Dev. Res., 72: 717-732.
    CrossRef  |  
  36. Tanaka, T., 2011. The effect of flavonoids on allergic diseases. Anti-Inflammatory Anti-Allergy Agents Med. Chem., 10: 374-381.
  37. Shima, Y., T. Tomita, T. Ishii, A. Morishima and Y. Maeda et al., 2011. Tocilizumab, a humanized Anti-interleukin-6 receptor antibody, ameliorated clinical symptoms and MRI findings of a patient with ankylosing spondylitis. Modern Rheumatol., 21: 436-439.
    CrossRef  |  Direct Link  |  
  38. Ogata, A., A. Morishima, T. Hirano, Y. Hishitani and K. Hagihara et al., 2011. Improvement of HbA1c during treatment with humanised Anti-interleukin 6 receptor antibody, tocilizumab. Ann. Rheumatic Dis., 70: 1164-1165.
    CrossRef  |  
  39. Nishida, S., T. Kawasaki, H. Kashiwagi, A. Morishima and Y. Hishitani et al., 2011. Successful treatment of acquired hemophilia A, complicated by chronic GVHD, with tocilizumab. Modern Rheumatol., 21: 420-422.
    CrossRef  |  Direct Link  |  
  40. Narazaki, M., K. Hagihara, Y. Shima, A. Ogata, T. Kishimoto and T. Tanaka, 2011. Therapeutic effect of tocilizumab on two patients with polymyositis. Rheumatology, 50: 1344-1346.
    Direct Link  |  
  41. Tanaka, T., K. Hagihara, Y. Shima, M. Narazaki, A. Ogata, I. Kawase and T. Kishimoto, 2010. Treatment of a patient with remitting seronegative, symmetrical synovitis with pitting oedema with a humanized anti-interleukin-6 receptor antibody, tocilizumab. Rheumatology, 49: 824-826.
    CrossRef  |  
  42. Tanaka, T., I. Kawase and T. Kishimoto, 2010. Reply to interleukin-6 as a target in spondyloarthritis. Arthrit. Care Res., 62: 745-746.
  43. Tanaka, T., A. Ogata and M. Narazaki, 2010. Tocilizumab for the treatment of rheumatoid arthritis. Expert Rev. Clin. Immunol., 6: 843-854.
    CrossRef  |  
  44. Shima, Y., Y. Kuwahara, H. Murota, S. Kitaba and M. Kawai et al, 2010. The skin of patients with systemic sclerosis softened during the treatment with anti-IL-6 receptor antibody tocilizumab. Rheumatology, 49: 2408-2412.
    CrossRef  |  
  45. Oji, Y., Y. Oka, S. Nishida, A. Tsuboi and M. Kawakami et al., 2010. WT1 peptide vaccine induces reduction in minimal residual disease in an Imatinib-treated CML patient. Eur. J. Haematol., 85: 358-360.
    CrossRef  |  
  46. Ogata, A., M. Mori, S. Hashimoto, Y. Yano and T. Fujikawa et al., 2010. Minimal influence of tocilizumab on IFN-γ synthesis by tuberculosis antigens. Modern Rheumatol., 20: 130-133.
    CrossRef  |  
  47. Narazaki, M., M. Segarra, X. Hou, T. Tanaka, X. Li and G. Tosato, 2010. Oligo-guanosinenucleotide induces Neutropilin-1 internalization in endothelial cells and inhibits angiogenesis. Blood, 116: 3099-3107.
  48. Hagihara, K., I. Kawase, T. Tanaka and T. Kishimoto, 2010. Tocilizumab ameliorates clinical symptoms in polymyalgia rheumatica. J. Rheumatol., 37: 1075-1076.
    CrossRef  |  
  49. Terabe, F., M. Kitano, M. Kawai, Y. Kuwahara and T. Hirano et al., 2009. Imatinib mesylate inhibited rat adjuvant arthritis and PDGF-dependent growth of synovial fibroblast via interference with the Akt signaling pathway. Modern Rheumatol., 19: 522-529.
    CrossRef  |  
  50. Tanaka, T., Y. Kuwahara, Y. Shima, T. Hirano and M. Kawai et al., 2009. Successful treatment of reactive arthritis with a humanized anti-interleukin-6 receptor antibody, tocilizumab. Arthrit. Care Res., 61: 1762-1764.
    CrossRef  |  
  51. Ohta, K., T. Miyamoto, T. Amagasaki and M. Yamamoto, 2009. Efficacy and safety of omalizumab in an Asian population with moderate-to-severe persistent asthma. Respirology, 14: 1156-1165.
    CrossRef  |  
  52. Ogata, F.T., K. Nakanishi, M. Kawai, Y. Kuwahara and T. Hirano et al., 2009. Etanercept improved primary biliary cirrhosis associated with rheumatoid arthritis. Joint. Bone. Spine, 76: 105-107.
    CrossRef  |  Direct Link  |  
  53. Nishida, S., K. Hagihara, Y. Shima, M. Kawai and Y. Kuwahara et al., 2009. Rapid improvement of AA amyloidosis with humanised anti-interleukin 6 receptor antibody treatment. Ann. Rheumat. Dis., 68: 1235-1236.
    CrossRef  |  
  54. Kudo-Tanaka, E., S. Nakatsuka, T. Hirano, M. Kawai and Y. Katada et al., 2009. A case of Mikulicz's disease with Th2-biased cytokine profile: Possible feature discriminable from Sjogren's syndrome. Modern Rheumatol., 19: 691-695.
    CrossRef  |  
  55. Kawai, M., T. Hirano, J. Arimitsu, S. Higa and Y. Kuwahara et al., 2009. Effect of enzymatically modified isoquercitrin, a flavonoid, on symptoms of Japanese cedar pollinosis: A randomized double-blind placebo-controlled trial. Int. Arch. Allergy Immunol., 149: 359-368.
    CrossRef  |  PubMed  |  
  56. Kawai, M., K. Hagihara, T. Hirano, Y. Shima and Y. Kuwahara et al., 2009. Sustained response to tocilizumab, anti-interleukin-6 receptor antibody, in two patients with refractory relapsing polychondritis. Rheumatology, 48: 318-319.
    CrossRef  |  PubMed  |  
  57. Hirano, T., M. Kawai, J. Arimitsu, M. Ogawa and Y. Kuwahara et al., 2009. Preventative effect of a flavonoid, enzymatically modified isoquercitrin on ocular symptoms of Japanese cedar pollinosis. Allergol. Int., 58: 373-382.
    CrossRef  |  
  58. Nishikawa, T., K. Hagihara, S. Serada, T. Isobe and A. Matsumura et al., 2008. Transcriptional complex formation of c-Fos, STAT3, and hepatocyte NF-1 alpha is essential for cytokine-driven C-reactive protein gene expression. J. Immunol., 180: 3492-3501.
    PubMed  |  
  59. Miyasaka, N., 2008. Clinical investigation in highly disease-affected rheumatoid arthritis patients in Japan with adalimumab applying standard and general evaluation: The CHANGE study. Mod. Rheumatol., 18: 252-262.
  60. Kuwahara, Y., Y. Shima, M. Kawai, K. Hagihara and T. Hirano et al., 2008. What kind of durometer is best suited for the assessment of skin disease in systemic sclerosis? Comment on the article by Kissin et al? Arthritis Rheum, Vol. 59. 10.1002/art.23543.
    CrossRef  |  Direct Link  |  
  61. Kuwahara, Y., Y. Shima, D. Shirayama, M. Kawai and K. Hagihara et al., 2008. Quantification of hardness, elasticity and viscosity of the skin of patients with systemic sclerosis using a novel sensing device (Vesmeter): A proposal for a new outcome measurement procedure. Rheumatology, 47: 1018-1024.
    PubMed  |  
  62. Serada, S., M. Fujimoto, T. Takahashi, P. He and A. Hayashi et al., 2007. Proteomic analysis of autoantigens associated with systemic lupus erythematosus: Anti-aldolase a antibody as a potential marker of lupus nephritis. Proteomics-Clin. Appl., 1: 185-191.
    CrossRef  |  Direct Link  |  
  63. Kawai, M., T. Hirano, S. Higa, J. Arimitsu and M. Maruta et al., 2007. Flavonoids and related compounds as anti-allergic substances. Allergol. Int., 56: 113-123.
    PubMed  |  Direct Link  |  
  64. He, P., T. Naka, S. Serada, M. Fujimoto and T. Tanaka et al., 2007. Proteomics-based identification of α-enolase as a tumor antigen in non-small lung cancer. Cancer Sci., 98: 1234-1240.
    CrossRef  |  Direct Link  |  
  65. Hayashi, N., T. Yoshimoto, K. Izuhara, K. Matsui, T. Tanaka and K. Nakanishi, 2007. T helper 1 cells stimulated with ovalbumin and IL-18 induce airway hyperresponsiveness and lung fibrosis by IFN-γ and IL-13 production. Proc. Natl. Acad. Sci., 104: 14765-14770.
    PubMed  |  
  66. Ouyang, X., M. Fujimoto, R. Nakagawa, S. Serada and T. Tanaka et al., 2006. SOCS-2 interferes with myotube formation and potentiates osteoblast differentiation through upregulation of JunB in C2C12 cells. J. Cell Physiol., 207: 428-436.
    CrossRef  |  
  67. Matsumoto, T., T. Tanaka and I. Kawase, 2006. Infliximab for rheumatoid arthritis in a patient with tuberculosis. N. Engl. J. Med., 355: 740-741.
    Direct Link  |  
  68. Kuwahara, Y., Y. Shima, T. Tanaka, H. Kimura, Y. Hoshida, K. Aozasa and I. Kawase, 2006. Successful treatment with intravenous cyclophosphamide pulse therapy of severe intestinal involvement in Wegener's granulomatosis. Scand J. Rheumatol., 35: 243-245.
    Direct Link  |  
  69. Katada, Y., Y. Harada, N. Azuma, K. Matsumoto and H. Terada et al., 2006. Minocycline-induced vasculitis fulfilling the criteria of polyarteritis nodosa. Mod. Rheumatol., 16: 256-259.
    CrossRef  |  Direct Link  |  
  70. Hirano, T., S. Higa, J. Arimitsu, T. Naka and A. Ogata et al., 2006. Luteolin, a flavonoid, inhibits AP-1 activation by basophils. Biochem. Biophys. Res. Commun., 340: 1-7.
    CrossRef  |  
  71. Hirano, T., J. Arimitsu, S. Higa, T. Naka and A. Ogata et al., 2006. Luteolin, a flavonoid, inhibits CD40 ligand expression by activated human basophils. Int. Arch. Allergy Immunol., 140: 150-156.
    CrossRef  |  
  72. Hagihara, K., T. Nishikawa, A. Matsumura, J. Song, T. Tanaka and K. Yoshizaki, 2006. Analysis of cytokine-driven serum amyloid A expression based on the clinical results of IL-6 blocking therapy: A new cis-acting mechanism of STAT3. Inflammation Regenr., 26: 453-459.
  73. Arimitsu, J., T. Hirano, S. Higa, M. Kawai and T. Naka et al., 2006. IL-18 gene polymorphisms affect IL-18 production capability by monocytes. Biochem. Biophys. Res. Commun., 342: 1413-1416.
    Direct Link  |  
  74. Shima, Y., M. Iwano, K. Yoshizaki, T. Tanaka, I. Kawase and N. Nishimoto, 2005. All-trans-retinoic acid inhibits the development of mesangial proliferative glomerulonephritis in interleukin-6 transgenic mice. Nephron. Exp. Nephrol., 100: 54-62.
    Direct Link  |  
  75. Inaba, M., H. Saito, M. Fujimoto, S. Sumitani and T. Ohkawara et al., 2005. Suppressor of cytokine signaling 1 suppresses muscle differentiation through modulation of IGF-I receptor signal transduction. Biochem. Biophys. Res. Commun., 328: 953-961.
    CrossRef  |  
  76. Watanabe, D., S. Ezoe, M. Fujimoto, A. Kimura and Y. Saito et al., 2004. Suppressor of cytokine signalling-1 gene silencing in acute myeloid leukaemia and human haematopoietic cell lines. Br. J. Haematol., 126: 726-735.
    Direct Link  |  
  77. Tanaka, T., S. Higa, T. Hirano, J. Arimitsu and T. Naka et al., 2004. Is an appropriate intake of flavonoids a prophylactic means or complementary and alternative medicine for allergic diseases? Recent. Res. Devel. Allergy Clin. Immunol., 5: 1-14.
  78. Jiang, M., H. Tsukahara, Y. Ohshima, C. Zou and N. Ohta et al., 2004. Methylenetetrahydrofolate reductase polymorphism in patients with bronchial asthma. Int. Med. J., 11: 119-123.
  79. Iwashige, K., K. Kouda, M. Kouda, K. Horiuchi and M. Takahashi et al., 2004. Calorie restricted diet and urinary pentosidine in patients with rheumatoid arthritis. J. Physiol. Anthropol. Appl. Human Sci., 23: 19-24.
    Direct Link  |  
  80. Hirano, T., J. Arimitsu, S. Higa, T. Naka and A. Ogata et al., 2004. Flavonoids such as luteolin, fisetin and apigenin are inhibitors of interleukin-4 and interleukin-13 production by activated human basophils. Int. Arch. Allergy Immunol., 134: 135-140.
    CrossRef  |  PubMed  |  
  81. Tanaka, T., S. Higa, T. Hirano, M. Kotani, M. Matsumoto, A. Fujita and I. Kawase, 2003. Flavonoids as potential anti-allergic substances. Curr. Med. Chem. Anti-Inflamm. Anti-Allergy Agents, 2: 57-65.
  82. Higa, S., T. Hirano, M. Mayumi, M. Hiraoka and Y. Ohshima et al., 2003. Association between interleukin-18 gene polymorphism 105A/C and asthma. Clin. Exp. Allergy, 33: 1097-1102.
    CrossRef  |  Direct Link  |  
  83. Higa, S., T. Hirano, M. Kotani, M. Matsumoto and A. Fujita et al., 2003. Fisetin, a flavonol, inhibits TH2-type cytokine production by activated human basophils. J. Allergy Clin. Immunol., 111: 1299-1306.
    Direct Link  |  
  84. Higa, S., M. Kotani, M. Matsumoto, A. Fujita and T. Hirano et al., 2003. Administration of anti-interleukin 18 antibody fails to inhibit development of dermatitis in atopic dermatitis-model mice NC/Nga. Br. J. Dermatol., 149: 39-45.
    CrossRef  |  PubMed  |  
  85. Suido, H., T. Tanaka, T. Tabei, A. Takeuchi and M. Okita et al., 2002. A mixed green vegetable and fruit beverage decreased the serum level of low-density lipoprotein cholesterol in hypercholesterolemic patients. J. Agric. Food Chem., 50 : 3346-3350.
    PubMed  |  Direct Link  |  
  86. Matsumoto, M. Kotani, A. Fujita, S. Higa, T. Kishimoto, M. Suemura and T. Tanaka, 2002. Oral administration of persimmon leaf extract ameliorates skin symptoms and transepidermal water loss in atopic dermatitis model mice, NC/Nga. Br. J. Dermatol., 146: 221-221.
  87. Kasayama, S., T. Tanaka, K. Hashimoto, M. Koga and I. Kawase, 2002. Efficacy of glimepiride for the treatment of diabetes occurring during glucocorticoid therapy. Diabetes Care, 25: 2359-2360.
    CrossRef  |  PubMed  |  
  88. Higa, H., H. Hirata, S. Minami, S. Hashimoto, M. Suemura, Y. Saeki, I. Kawase and T. Tanaka, 2002. Autoimmune acquired form of angioedema that responded to danazol therapy. Intern. Med., 41: 398-402.
    PubMed  |  
  89. Yokota, A., M. Narazaki, Y. Shima, N. Murata and T. Tanaka et al., 2001. Preferential and persistent activation of the STAT1 pathway in rheumatoid synovial fluid cells. J. Rheumatol., 28: 1952-1959.
    PubMed  |  Direct Link  |  
  90. Yamaguchi, T., S. Ohshima, T. Tanaka, S. Tsukada and M. Matsushita et al., 2001. Renal crisis due to intimal hyperplasia in a patient with mixed connective tissue disease (MCTD) accompanied by pulmonary hypertension. Intern. Med., 40: 1250-1253.
    PubMed  |  
  91. Wang, W., T. Tanaka, H. Okamura, M. Sugita, S. Higa, T. Kishimoto and M. Suemura, 2001. Interleukin-18 enhances the production of interleukin-8 by eosinophils. Eur. J. Immunol., 31 : 1010-1016.
    CrossRef  |  PubMed  |  
  92. Tanaka, T., Y. Katada, S. Higa, H. Fujiwara and W. Wang et al., 2001. Enhancement of T helper 2 response in the absence of interleukin (IL-)6; An inhibition of IL-4-mediated T helper 2 cell differentiation by IL-6. Cytokine, 13: 193-201.
  93. Tanaka, T., K. Kouda, M. Kotani, A. Takeuchi and T. Tabei et al., 2001. Vegetarian diet ameliorates symptoms of atopic dermatitis through reduction of the number of peripheral eosinophils and of PGE2 synthesis by monocytes. J. Phsiol. Anthropol. Appl. Human Sci., 20: 353-361.
    PubMed  |  
  94. Tanaka, T., H. Tsutsui, T. Yoshimoto, M. Kotani and M. Matsumoto et al., 2001. Interleukin-18 is elevated in the sera from patients with atopic dermatitis and from atopic dermatitis model mice, NC/Nga. Int. Arch. Allergy Immunol., 125: 236-240.
    CrossRef  |  PubMed  |  
  95. Kouda, K., T. Tanaka, M. Kouda, H. Takeuchi, A. Takeuchi, H. Nakamura and M. Takigawa, 2000. Low-energy diet in atopic dermatitis patients: clinical findings and DNA damage. J. Physiol. Anthropol. Appl. Human Sci., 19: 225-228.
    PubMed  |  Direct Link  |  
  96. Kotani, M., M. Matsumoto, A. Fujita, S. Higa, W. Wang, M. Suemura, T. Kishimoto and T. Tanaka, 2000. Persimmon leaf extract and astragalin inhibit development of dermatitis and IgE elevation in NC/Nga mice. J. Allergy Clin. Immunol., 106: 159-166.
    CrossRef  |  PubMed  |  Direct Link  |  
  97. Sasai, M., Y. Saeki, S. Ohshima, K. Nishioka and T. Mima et al., 1999. Delayed onset and reduced severity of collagen-induced arthritis in interleukin-6-deficient mice. Arthritis Rheum., 42: 1635-1643.
    CrossRef  |  PubMed  |  
  98. Ohshima, S., Y. Saeki, T. Mima, M. Sasai and K. Nishioka et al., 1998. Interleukin 6 plays a key role in the development of antigen-induced arthritis. Proc. Natl. Acad. Sci., 95: 8222-8226.
    Direct Link  |  
  99. Maeda, K., T. Tanaka, Y. Katada, A. Horii and K. Nose et al., 1998. Bronchial and nasal responsiveness in atopic asthma and allergic rhinitis patients: relationship of local responsiveness to cytokine production by peripheral blood mononuclear cells. Allergol. Int., 47: 45-51.
  100. Saiki, O., H. Uda, M. Hayashi, T. Tanaka and Y. Katada et al., 1997. In vivo but not In vivo stimulations rescue of the defective class switching to IgG or IgA in B-cells of immunodeficiency with hyper IgM. Clin. Immunol. Immunopathol., 83: 287-292.
    PubMed  |  Direct Link  |  
  101. Tanaka, T., Y. Katada, H. Ochi, M. Suemura and T. Kishimoto, 1996. IL-2, IL-4, IL-6, IL-10, IFN-gamma, their Receptors, Modulation of their Actions and Role in Allergic Responses. In: Immunopharmacology of Allergic Diseases, Townley R.G. and Argawal D.K. Marcel (Eds.). Dekker, Inc., Switzerland, pp: 365-381.
  102. Ochi, H., T. Tanaka, Y. Katada, T. Naka and M. Aitani et al., 1996. Peripheral blood T lymphocytes and basophils, freshly isolated from house-dust-mite-sensitive patients, produce lnterleukin-4 in response to allergen-specific stimulation. Int. Arch. Allergy Immunol., 111: 253-261.
    CrossRef  |  
  103. Ochi, H., T. Tanaka, Y. Katada, T. Naka and M. Aitani et al., 1996. Functional disturbance of naive T lymphocytes in very high IgE producers: Depletion of interleukin-4-induced interleukin-4-producing cells. Int. Arch. Allergy Immunol., 109: 236-242.
    PubMed  |  Direct Link  |  
  104. Katada, Y., T. Tanaka, H. Ochi, M. Aitani and A. Yokota et al., 1996. B cell-B cell interaction through intercellular adhesion molecule-1 and lymphocyte functional antigen-1 regulates immunoglobulin E synthesis by B cells stimulated with interleukin-4 and anti-CD40 antibody. Eur. J. Immunol., 26: 192-200.
    CrossRef  |  
  105. Saiki, O., T. Tanaka, Y. Wada, H. Uda and A. Inoue et al., 1995. Signaling through CD40 rescues IgE but not IgG or IgA secretion in X-linked immunodeficiency with hyper-IgM. J. Clin. Invest., 95: 510-514.
    CrossRef  |  Direct Link  |  
  106. Tanaka, T., Y. Katada, M. Suemura and T. Kishimoto, 1993. Interleukin-6. In: Cytokine Regulation of Humoral Immunity: Basic and Clinical Aspects, Snapper C.M. (Ed.). John Wiley and Sons, Ltd., England, pp: 251-272.
  107. Tanaka, T., J. Hu-Li, R.A. Seder, B.F. de St Groth and W.E. Paul, 1993. Interleukin 4 suppresses interleukin 2 and interferon gamma production by naive T cells stimulated by accessory cell-dependent receptor engagement. Proc. Natil. Acad. Sci., 90: 5914-5918.
    Direct Link  |  
  108. Tanaka, T., C.C. Chu and W.E. Paul, 1992. An antisense oligonucleotide complementary to a sequence in I gamma 2b increases gamma 2b germline transcripts, stimulates B cell DNA synthesis and inhibits immunoglobulin secretion. J. Exp. Med., 175: 597-607.
    CrossRef  |  
  109. Saiki, O., H. Ogawa, T. Ikeda, T. Masuno and T. Tanaka et al., 1992. Acquired T cell specific deficiency other than acquired immunodeficiency syndrome (AIDS). Intern. Med., 31: 11-16.
    PubMed  |  Direct Link  |  
  110. Paul, W.E., R.A. Seder, J. Hu-Li, T. Tanaka and S.Z. Ben-Sasson, 1992. IL-4 is a major determinant of T cell lymphokine-producing phenotypes. Proceedings of the 8th International Congress of Immunology, August 23-28, 1992, Budapest, Hungary, pp: 347-354.
  111. Tanaka, T., S.Z. Ben-Sasson and W.E. Paul, 1991. IL-4 increases IL-2 production by T cells in response to accessory cell-independent stimuli. J. Immunol., 146: 3831-3839.
    Direct Link  |  
  112. Yoshimoto, T., Nakanishi, K. Matsui, K. Hirose and S. Hiroishi et al., 1990. IL-5 up-regulates but IL-4 down-regulates IL-2R expression on a cloned B lymphoma line. J. Immunol., 144: 183-190.
    Direct Link  |  
  113. Saiki, O., T. Tanaka and S. Kishimoto, 1990. Defective expression of p70/75 interleukin 2 receptor in T cells from patients with systemic lupus erythematosus: A possible defect in the process of increased intracellular calcium leading to p70/75 expression. J. Rheumatol., 17: 1303-1307.
    PubMed  |  
  114. Nishio, S.I., S. Negoro, T. Hosokawa, H. Hara and T. Tanaka et al., 1990. The effect of taurine on age-related immune decline in mice: the effect of taurine on T cell and B cell proliferative response under costimulation with ionomycin and phorbol myristate acetate. Mech. Ageing Dev., 52: 125-139.
    CrossRef  |  Direct Link  |  
  115. Tanaka, T., S. Kishimoto and O. Saiki, 1989. Different induction of p55 and p70/75 interleukin-2 receptor subunits in human cells. Biochem. Biophys Res. Commun., 164: 686-692.
    CrossRef  |  
  116. Tanaka, T., O. Saiki, S. Negoro, T. Igarashi and T. Kuritani et al., 1989. Decreased expression of interleukin-2 binding molecules (p70/75) in T cells from patients with systemic lupus erythematosus. Arthritis Rheumatism, 32: 552-559.
    CrossRef  |  
  117. Matsuzaki, N., F. Saji, T. Okada, K. Sawai and T. Kameda et al., 1989. Demonstration of functional immaturity of signal transduction pathways in human cord T cells. Cellular Immunol., 124: 252-263.
    CrossRef  |  
  118. Doi, S., O. Saiki, T. Hara, T. Sugita and K. Ha-Kawa et al., 1989. Administration of recombinant IL-2 augments the level of serum IgM in an IL-2 deficient patient. Eur. J. Pediatrics, 148: 630-633.
    CrossRef  |  
  119. Tanaka, T., O. Saiki, S. Doi, S. Negoro and S. Kishimoto, 1988. Interleukin 2 functions through novel interleukin 2 binding molecules in T cells. J. Immunol., 140: 470-473.
    Direct Link  |  
  120. Tanaka, T., O. Saiki, S. Doi, M. Suemura, S. Negoro and S. Kishimoto, 1988. Expression of novel interleukin 2 binding molecules and their functional roles in human B cell differentiation. J. Clin. Invest., 82: 316-321.
    Direct Link  |  
  121. Tanaka, T., O. Saiki, S. Doi, M. Fujii and K. Sugamura et al., 1988. Novel receptor-mediated internalization of interleukin 2 in B cells. J. Immunol., 140: 866-870.
    Direct Link  |  
  122. Saiki, O., T. Tanaka, S. Doi and S. Kishimoto, 1988. Expression and the functional role of a p70/75 interleukin 2-binding molecule in human B cell. J. Immunol., 140: 853-858.
    Direct Link  |  
  123. Hara, H., T. Tanaka, S. Negoro, Y. Deguchi, S. Nishio, O. Saiki and S. Kishimoto, 1988. Age-related changes of expression of IL-2 receptor subunits and kinetics of IL-2 internalization in T cells after mitogenic stimulation. Mech. Ageing Dev., 45: 167-175.
    CrossRef  |  
  124. Doi, S., O. Saiki, T. Tanaka, K. Ha-Kawa and T. Igarashi et al., 1988. Cellular and genetic analyses of IL-2 production and IL-2 receptor expression in a patient with familial T-cell-dominant immunodeficiency. Clin. Immunol. Immunopathol., 46: 24-36.
    CrossRef  |  
  125. Tanaka, T., O. Saiki, M. Hatakeyama, T. Kono and H. Mori et al., 1987. Functional interleukin 2 receptors on B cells lacking Tac antigens. Eur. J. Immunol., 17: 1379-1382.
    CrossRef  |  
  126. Saiki, O., Y. Saeki, T. Tanaka, H. Hara, S. Negoro, T. Igarashi and S. Kishimoto, 1987. Development of selective IgM deficiency in systemic lupus erythematosus patients with disease of long duration. Arthritis Rheumatism, 30: 1289-1292.
    CrossRef  |  
  127. Negoro, S., H. Hara, S. Miyata, O. Saiki and T. Tanaka et al., 1987. Age-related changes of the function of T cell subsets: Predominant defect of the proliferative response in CD8 positive T cell subset in aged persons. Mech. Ageing Dev., 39: 263-279.
    CrossRef  |  
  128. Hara, H., S. Negoro, S. Miyata, O. Saiki and K. Yoshizaki et al., 1987. Age-associated changes in proliferative and differentiative response of human B cells and production of T cell-derived factors regulating B cell functions. Mech. Ageing Dev., 38: 245-258.
    CrossRef  |  
  129. Negoro, S., H. Hara, S. Miyata, O. Saiki and T. Tanaka et al., 1986. Mechanisms of age-related decline in antigen-specific T cell proliferative response: IL-2 receptor expression and recombinant IL-2 induced proliferative response of purified Tac-positive T cells. Mech. Ageing Dev., 36: 223-241.
    CrossRef  |